Factors associated with left ventricular reverse remodelling after percutaneous coronary intervention in patients with left ventricular systolic dysfunction.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
08 01 2021
Historique:
received: 15 05 2020
accepted: 22 12 2020
entrez: 9 1 2021
pubmed: 10 1 2021
medline: 10 8 2021
Statut: epublish

Résumé

Percutaneous coronary intervention (PCI) is sometimes considered as an alternative therapeutic strategy to surgical revascularization in patients with coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). However, the types or conditions of patients that receive the clinical benefit of left ventricular reverse remodelling (LVRR) remain unknown. The purpose of this study was to investigate the determinants of LVRR following PCI in CAD patients with reduced LVEF. From 4394 consecutive patients who underwent PCI, a total of 286 patients with reduced LV systolic function (LVEF < 50% at initial left ventriculography) were included in the analysis. LVRR was defined as LV end-systolic volume reduction ≥ 15% and improvement of LVEF ≥ 10% at 6 months follow-up left ventriculography. Patients were divided into LVRR (n = 63) and non-LVRR (n = 223) groups. Multivariate logistic regression analysis revealed that unprotected left main coronary artery (LMCA) intervention was significantly associated with LVRR (P = 0.007, odds ratios [OR] 4.70, 95% confidence interval [CI] 1.54-14.38), while prior PCI (P = 0.001, OR 0.35, 95% CI 0.19-0.66), presence of in-stent restenosis (P = 0.016, OR 0.32, 95% CI 0.12-0.81), and presence of de-novo stenosis (P = 0.038, OR 0.36, 95% CI 0.14-0.95) were negatively associated with LVRR. These data suggest the potential prognostic benefit of unprotected LMCA intervention for LVRR and importance of angiographic follow-up in patients with CAD and LV systolic dysfunction.

Identifiants

pubmed: 33420237
doi: 10.1038/s41598-020-80491-y
pii: 10.1038/s41598-020-80491-y
pmc: PMC7794568
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

239

Références

Circulation. 2014 Jun 10;129(23):2388-94
pubmed: 24700706
J Am Coll Cardiol. 2002 Sep 4;40(5):970-5
pubmed: 12225725
Int J Cardiol. 2016 Oct 15;221:128-33
pubmed: 27400309
J Diabetes Investig. 2012 Feb 20;3(1):39-40
pubmed: 24843544
N Engl J Med. 2016 Dec 8;375(23):2284-2285
pubmed: 27797298
J Am Coll Cardiol. 1997 Apr;29(5):1060-6
pubmed: 9120160
Circulation. 2005 Sep 13;112(11):1580-6
pubmed: 16144994
Lancet. 1997 Feb 8;349(9049):375-80
pubmed: 9033462
Circulation. 1997 Oct 7;96(7):2197-205
pubmed: 9337190
J Am Coll Cardiol. 2011 Sep 27;58(14):1426-32
pubmed: 21939824
J Am Coll Cardiol. 2017 May 2;69(17):2212-2241
pubmed: 28291663
J Am Coll Cardiol. 2011 Jun 14;57(24):2416-23
pubmed: 21658562
J Am Coll Cardiol. 2002 Apr 3;39(7):1151-8
pubmed: 11923039
Circulation. 1992 Aug;86(2):431-8
pubmed: 1638712
N Engl J Med. 2011 May 5;364(18):1718-27
pubmed: 21463149
Circulation. 1992 May;85(5):1699-705
pubmed: 1572028
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264
pubmed: 30153967
Circ J. 2018 Dec 25;83(1):198-208
pubmed: 30416191
JACC Cardiovasc Interv. 2009 Aug;2(8):739-47
pubmed: 19695542
Lancet. 2019 Oct 12;394(10206):1325-1334
pubmed: 31488373
J Am Coll Cardiol. 1986 Apr;7(4):729-42
pubmed: 3514727
Circ Cardiovasc Interv. 2015 Mar;8(3):e001846
pubmed: 25744763
Circulation. 1993 Nov;88(5 Pt 1):2277-83
pubmed: 8222122
Circulation. 2005 Oct 18;112(16):2530-7
pubmed: 16230504
Nat Rev Cardiol. 2018 Jun;15(6):321-331
pubmed: 29599504
BMJ. 2015 Nov 04;351:h5392
pubmed: 26537292
N Engl J Med. 2019 Nov 7;381(19):1820-1830
pubmed: 31562798
J Am Coll Cardiol. 2016 Sep 6;68(10):999-1009
pubmed: 27585503
Ann Noninvasive Electrocardiol. 2002 Apr;7(2):98-105
pubmed: 12049680
EuroIntervention. 2013 Nov;9(7):809-16
pubmed: 24280157
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
J Am Coll Cardiol. 2011 Mar 29;57(13):1468-76
pubmed: 21435516

Auteurs

Yusuke Adachi (Y)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Arihiro Kiyosue (A)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. kiyosue-tky@umin.ac.jp.

Jiro Ando (J)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Takuya Kawahara (T)

Clinical Research Promotion Center, The University of Tokyo Hospital, Tokyo, Japan.

Satoshi Kodera (S)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Shun Minatsuki (S)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hironobu Kikuchi (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Toshiro Inaba (T)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hiroyuki Kiriyama (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Kazutoshi Hirose (K)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hiroki Shinohara (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Akihito Saito (A)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Takayuki Fujiwara (T)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hironori Hara (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Kazutaka Ueda (K)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Kenichi Sakakura (K)

Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Masaru Hatano (M)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Mutsuo Harada (M)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Eiki Takimoto (E)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hiroshi Akazawa (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Hiroyuki Morita (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Shin-Ichi Momomura (SI)

Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Hideo Fujita (H)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Issei Komuro (I)

Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH